1. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations
- Author
-
Emanuele S.G. d'Amore, Miguel A. Piris, Carlo Visco, Maria Chiara Tisi, Maurilio Ponzoni, Govind Bhagat, Jinfen Wang, Karen Dybkær, Ken H. Young, Zijun Y. Xu-Monette, J. Han van Krieken, L. Jeffrey Medeiros, Andrés J.M. Ferreri, Eric D. Hsi, Santiago Montes-Moreno, Alexandar Tzankov, Michael Boe Møller, Lijuan Deng, Visco, C., Wang, J., Tisi, M. C., Deng, L., D'Amore, E. S. G., Tzankov, A., Montes-Moreno, S., Dybkaer, K., Bhagat, G., Hsi, E. D., Van Krieken, J. H., Ponzoni, M., Ferreri, A. J. M., Moller, M. B., Piris, M. A., Medeiros, L. J., Xu-Monette, Z. Y., and Young, K. H.
- Subjects
hepatitis C virus ,Male ,Cancer Research ,Pathology ,Lymphoma ,Genes, myc ,Hepacivirus ,medicine.disease_cause ,Translocation, Genetic ,0302 clinical medicine ,International Prognostic Index ,immune system diseases ,hemic and lymphatic diseases ,Hepacivirus/isolation & purification ,Proto-Oncogene Proteins c-bcl-2/analysis ,virus diseases ,Proto-Oncogene Proteins c-bcl-6/genetics ,myc ,Middle Aged ,BCL6 ,Diffuse ,3. Good health ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,030220 oncology & carcinogenesis ,Proto-Oncogene Proteins c-bcl-6 ,Female ,Lymphoma, Large B-Cell, Diffuse ,SIKE-1 ,Adult ,medicine.medical_specialty ,BCL2 ,Proliferative index ,Hepatitis C virus ,diffuse large B-cell lymphoma ,Translocation ,Biology ,Virus ,03 medical and health sciences ,Genetic ,Large B-Cell ,medicine ,Journal Article ,Humans ,Case-Control Studies ,Molecular Diagnostics ,medicine.disease ,Genes ,Hepatitis C Virus Positive ,Lymphoma, Large B-Cell, Diffuse/genetics ,Cancer research ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
BACKGROUND: The clinical presentation of patients with hepatitis C virus (HCV)-positive diffuse large B-cell lymphoma (DLBCL) is different from their HCV-negative counterparts, but the underlying molecular and pathological characteristics are largely under investigated. The virus has a role in lymphomagenesis, as witnessed by the curative potential of antiviral therapy in HCV-related low-grade B-cell lymphomas.METHODS: We performed a case-control study including 44 HCV-positive cases of de novo DLBCL, comparing them with 132 HCV-negative patients as controls (ratio 3 to 1). Cases and controls were matched for age, lactate dehydrogenase level and international prognostic index at presentation. Patients were studied by gene expression profiling for cell-of-origin determination and to perform differential expression analysis between groups, fluorescence in-situ hybridisation and immunohistochemistry for MYC, BCL2 and BCL6, TP53 mutations, and diagnostic specimens reviewed to exclude transformation from low-grade lymphoma.RESULTS: Compared to the HCV-negative controls, patients with HCV-positive de novo DLBCL had differential expression of genes that regulate innate immune response and modulate apoptotic pathways, have higher proliferative index, and lack BCL2 translocations.CONCLUSIONS: HCV-positive DLBCL have distinct molecular and pathological features compared to the HCV-negative counterparts.British Journal of Cancer advance online publication, 26 September 2017; doi:10.1038/bjc.2017.345 www.bjcancer.com.
- Published
- 2017